Prostaglandins

Prostaglandins

 

 

Latanoprost,130209-82-4,>99%
Latanoprost
Latanoprost,130209-82-4,>99%
CAS
130209-82-4
Molecular Formula
C26H40O5 
Molecular Weight
432.597
Systematic Name
Xalatan
Assay
99.0%
Certificate of analysis
Latanoprost,130209-82-4,>99%
View via PDF file
Latanoprost,130209-82-4,>99%
Specification
Appearance
Colorless or pale yellow oil
Complies
Identification
(1) by HPLC
the retention tiem of the major peak
corresponds to the standard
preparation.
Complies
(2) by IR
Both the test sample and the
reference standard exhibit the same
intensity of the absorption at the
same wave.
Complies
Optical rotation
+32.0º to +38.0º
35º
Water
Not more than 0.5%
0.2%
Residual substance
15(s)-cis isomer: N.M.T:0.1%
Not detected
15(s)-trans isomer: N.M.T:0.1%
Not detected
15(r)-trans isomer: N.M.T:0.1%
Not detected
Any single impurity: N.M.T:0.1%
0.06%
Total impurities: N.M.T:1.0%
0.11%
Residual solvents
n-Hexane: N.M.T:0.05%
Not detected
Ethanol: 1.0%
0.11%
Assay
96.0% to 102.0%
99.3%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Prostagandins
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(s).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.